Skip to main content

Viruses, Immune stimulation and RNA Interference in Oncology Network

Objective

The Viruses, Immune stimulation and RNA Interference in Oncology Network (VIRION) is focused on the execution of an internationally competitive cancer research project focused on the development of a novel therapeutic regime by combining immune therapy with oncolytic virotherapy and RNA interference techniques.

Recent clinical successes have shown the immune system to be a powerful ally in the fight against cancer. While surgery, chemotherapy and radiation therapy remain the first lines of treatment for most tumors, immunotherapy regimens have had astonishing clinical successes. Furthermore, recent studies have shown that pre-existing lymphocytic infiltration of tumors is associated with superior prognostic outcomes in a variety of cancers and might improve cancer therapies targeting immune checkpoints. A recent development in the immunotherapy field is adoptive cell therapy (ACT). In ACT lymphocytes from cancer patients are expanded ex vivo into more favorable numbers, they can be modified genetically or stimulated to relieve immune suppression and infused back into the patient. In clinical trials, ACT has resulted in anti tumor responses.

However, immune suppression in the tumor microenvironment limits the efficacy of immunotherapy and remains a major hurdle. We aim to potentiate the antitumor immune reaction in the tumor microenvironment through the combination of immune therapy and oncolytic virotherapy. Oncolytic viruses are developed to specifically target and destroy tumor cells. In pre-clinical models, oncolytic adenoviruses have proven a powerful tool in the elimination of tumors, not only by their direct lytic effects but also by their triggering of a subsequent tumor inflammation and enhanced lymphocytic infiltration. VIRION will address how these immune responses can be further enhanced by addition of immune modulating factors and/or siRNA targeting tumor genes that play an immune suppressive role in the tumor micro environment.

Field of science

  • /medical and health sciences/clinical medicine/surgery
  • /natural sciences/biological sciences/microbiology/virology
  • /medical and health sciences/basic medicine/immunology/immunotherapy
  • /medical and health sciences/basic medicine/immunology
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology

Call for proposal

H2020-MSCA-ITN-2014
See other projects for this call

Funding Scheme

MSCA-ITN-EID - European Industrial Doctorates

Coordinator

STICHTING VUMC
Address
De Boelelaan 1117
1081 HV Amsterdam
Netherlands
Activity type
Research Organisations
EU contribution
€ 510 748,56

Participants (3)

TILT BIOTHERAPEUTICS OY
Finland
EU contribution
€ 538 290,72
Address
Haartmaninkatu 3 C
00290 Helsinki
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ORCA Therapeutics BV
Netherlands
EU contribution
€ 255 374,28
Address
Jonkerbosplein 52
6534AB Nijmegen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
STICHTING VU

Participation ended

Netherlands
EU contribution
€ 0
Address
De Boelelaan 1105
1081 HV Amsterdam
Activity type
Higher or Secondary Education Establishments

Partners (5)

Adiutide Pharmaceuticals GmbH
Germany
Address
Zum Talblick 31
61479 Glashuetten
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Diamond Biopharm Limited
United Kingdom
Address

Sawbridgeworth
Activity type
Other
Hyphen Projects BV
Netherlands
Address

Hilversum
Activity type
Higher or Secondary Education Establishments
Netherlands society of gene and cell therapy
Netherlands
Address

Amsterdam
Activity type
Higher or Secondary Education Establishments
Quintess Consultancy BV
Netherlands
Address

Schiedam
Activity type
Other